SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Panacea Biotec - Quaterly Results

12 Aug 2023 Evaluate
The sales figure stood at Rs. 894.10 millions for the June 2023 quarter. The mentioned figure indicates a growth of about 45.76% as compared to Rs. 613.40 millions during the year-ago period.The Total Profit for the quarter ended June 2023 of Rs. 12.90 millions grew from Rs.-742.40 millions Operating profit Margin for the quarter ended June 2023 improved to 101.50% as compared to -654.90% of corresponding quarter ended June 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202306 202206 % Var 202306 202206 % Var 202303 202203 % Var
Sales 894.10 613.40 45.76 894.10 613.40 45.76 2570.70 2355.00 9.16
Other Income 33.40 65.30 -48.85 33.40 65.30 -48.85 344.30 125.70 173.91
PBIDT 101.50 -654.90 -115.50 101.50 -654.90 -115.50 -281.90 -601.10 -53.10
Interest 34.60 24.70 40.08 34.60 24.70 40.08 100.60 70.40 42.90
PBDT 66.90 -679.60 -109.84 66.90 -679.60 -109.84 -382.50 -671.50 -43.04
Depreciation 54.00 62.80 -14.01 54.00 62.80 -14.01 245.00 264.30 -7.30
PBT 12.90 -742.40 -101.74 12.90 -742.40 -101.74 -627.50 -935.80 -32.95
TAX 0.00 0.00 0.00 0.00 0.00 0.00 247.90 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 247.90 0.00 0.00
PAT 12.90 -742.40 -101.74 12.90 -742.40 -101.74 -875.40 -935.80 -6.45
Equity 61.30 61.30 0.00 61.30 61.30 0.00 61.30 61.30 0.00
PBIDTM(%) 11.35 -106.77 -110.63 11.35 -106.77 -110.63 -10.97 -25.52 -57.04

Panacea Biotec Share Price

342.05 -15.95 (-4.46%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×